The pharmaceutical company Almirall, member of CATALONIA.HEALTH, launches the new Ebglyss treatment (lebrikizumab) in Spain. This monoclonal antibody is already available for the treatment of adult and teen patients with atopic dermatitis from moderate to severe and who are candidates for systemic therapy.  

This drug represents a significant advance in patients with atopic dermatitis from moderate to severe thanks to its precision, control and unique posology. This treatment, Almirall’s second biological in dermatology, is available in Spain after the European Commission’s marketing authorization in November 2023 and the Ministry of Health’s inclusion decision in June 2024. In addition, it is already available in several European countries such as Germany, the United Kingdom, Norway, Denmark and the Czech Republic.  

Lidia Martín, CEO of Almirall Iberia, has underlined the importance of this launch in Spain: "The availability of lebrikizumab marks a milestone in addressing the unmet needs of people with moderate to severe atopic dermatitis. At Almirall we have been committed to looking for treatments that help to cover people’s medical needs. As the only Spanish company with two Biologicals on the market, we are proud to be at the forefront of dermatological innovation and to be able to serve both the health community and patients."